New enzyme targets for selective cancer therapies - (Science Daily via NewsPoints Desk)

  • In study findings published in Cell Death & Disease, researchers say a first-of-its-kind neuraminidase inhibitor turned glioblastoma cancer stem cells into normal cells, reported Science Daily.
  • According to Christopher Cairo, whose team synthesized the compound, "this is the first proof-of-concept showing a selective neuraminidase inhibitor can have a real effect in human cancer cells."
  • He noted that while "it isn't a drug yet…it establishes a new target that we think can be used for creating new, more selective drugs."
  • In its current form, the compound could not be used as a drug, Cairo explained, largely because it was not designed to breach the blood-brain barrier making it difficult to reach the target cells.
  • However, his team is already working on improving the compound, and developing and testing new and existing inhibitors using a panel of in vitro assays they developed.

To read more NewsPoints articles, click here.

Reference Articles